Product image of Olmesartan Medoxomil/Amlodipine/Hct Innovis (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide) supplied by GNH India

Olmesartan Medoxomil/Amlodipine/Hct Innovis

Active Ingredient:
Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide
Origin:
EU

Olmesartan Medoxomil/Amlodipine/Hct Innovis (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hct Innovis, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood‑pressure control beyond a single agent.

GNH India supplies Olmesartan Medoxomil/Amlodipine/Hct Innovis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Innovis Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan Medoxomil/Amlodipine/HCT Innovis is used in cardiovascular therapy to manage high blood pressure through multiple mechanisms.

  • Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient.
  • Hypertensive urgency (when oral therapy is appropriate): helps achieve target pressures safely.
  • Combination therapy for patients with resistant hypertension: simplifies regimens and improves adherence.

How It Works

  • The combination product lowers blood pressure by three complementary actions: olmesartan blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide promotes renal sodium and water excretion, reducing plasma volume. Together these effects produce sustained antihypertensive activity.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness or light‑headedness: especially after standing.
  • Fatigue: general tiredness.
  • Increased urination: due to diuretic component.
  • Flushing: transient warmth sensation.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of face, lips or throat.
  • Severe electrolyte imbalance: notably low potassium or sodium.
  • Acute kidney injury: sudden decline in renal function.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Severe hypotension: symptomatic low blood pressure.
  • Allergic skin reactions: rash, Stevens‑Johnson syndrome.

Precautions & Warnings

Patients should be evaluated for specific health conditions and monitored during therapy.

  • Renal impairment: adjust monitoring, may need dose modification.
  • Hepatic disease: use with caution, monitor liver function.
  • Electrolyte disturbances: check potassium and sodium levels regularly.
  • Pregnancy: avoid use, especially in the second and third trimesters.
  • Concomitant use with other antihypertensives: risk of excessive blood‑pressure lowering.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan Medoxil/Amlodipine/HCT Innovis can interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

  • Aliskiren (in diabetic patients): may cause severe hypotension and renal dysfunction.
  • Potassium‑sparing diuretics or supplements: risk of hyperkalaemia.
  • Strong CYP3A4 inhibitors (e.g., itraconazole): increase amlodipine levels.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
  • Lithium: may increase lithium concentrations.
  • Antidiabetic agents: blood‑glucose may fall, requiring dose adjustment.

Frequently Asked Questions

Olmesartan Medoxomil/Amlodipine/HCT Innovis is a fixed‑dose combination tablet indicated for the treatment of hypertension, including cases where blood‑pressure control is not achieved with a single‑agent regimen. It is prescribed to help patients reach target blood‑pressure levels and reduce cardiovascular risk.

Olmesartan blocks the angiotensin II type‑1 receptor, preventing the hormone from causing vasoconstriction and aldosterone release. This results in relaxed blood vessels and lower blood pressure, complementing the calcium‑channel blocking action of amlodipine and the diuretic effect of hydrochlorothiazide.

The dose is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, comorbidities, and response to therapy. The prescriber determines the appropriate strength and dosing schedule for each patient.

Olmesartan Medoxomil/Amlodipine/HCT Innovis is generally contraindicated in pregnancy, especially in the second and third trimesters, due to potential fetal toxicity. Breastfeeding mothers should consult a healthcare professional, as the drugs may pass into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, this fixed‑dose combination offers three complementary mechanisms—angiotensin receptor blockade, calcium‑channel blockade, and diuresis—allowing more potent blood‑pressure reduction in a single tablet. It can improve adherence versus taking multiple separate pills and may be more effective than monotherapy in resistant hypertension.

Store the tablets at or below 25 °C in a dry place, protected from moisture and direct sunlight. Keep them in the original packaging until use to maintain stability and potency.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events can include angio‑edema, severe hypotension, acute kidney injury, significant electrolyte disturbances, and rare hepatic dysfunction. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or marked changes in urine output.

The combination is contraindicated in patients with known hypersensitivity to any component, severe renal or hepatic impairment, and in pregnant women. Caution is also advised for individuals with a history of angio‑edema or significant electrolyte abnormalities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT